Evommune (NYSE:EVMN) CEO Sells $381,736.38 in Stock

Evommune, Inc. (NYSE:EVMN – Get Free Report) CEO Luis Pena sold 16,787 shares of Evommune stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $22.74, for a total value of $381,736.38. Following the completion of the transaction, the chief executive officer owned 637,896 shares in the company, valued at $14,505,755.04. The trade was a 2.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Evommune Stock Down 4.0%

Evommune stock opened at $19.87 on Friday. The business has a 50-day simple moving average of $23.91. The company has a market capitalization of $715.68 million and a price-to-earnings ratio of -2.09. Evommune, Inc. has a 52 week low of $13.89 and a 52 week high of $33.20.

Get Evommune alerts:

Evommune (NYSE:EVMN – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. On average, analysts predict that Evommune, Inc. will post -2.86 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on EVMN. Clear Str raised Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Oppenheimer began coverage on Evommune in a research report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 target price on the stock. Wall Street Zen raised Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Evercore reissued an “outperform” rating and set a $55.00 target price on shares of Evommune in a research report on Tuesday, February 10th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 target price on shares of Evommune in a research report on Friday, April 10th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $49.25.

View Our Latest Stock Report on Evommune

Institutional Investors Weigh In On Evommune

A number of institutional investors have recently added to or reduced their stakes in the stock. EQT Fund Management S.a r.l. acquired a new stake in Evommune during the fourth quarter valued at approximately $84,395,000. RA Capital Management L.P. acquired a new stake in Evommune during the fourth quarter valued at approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC acquired a new stake in Evommune during the fourth quarter valued at approximately $32,989,000. Nan Fung Group Holdings Ltd acquired a new stake in Evommune during the fourth quarter valued at approximately $24,670,000. Finally, JPMorgan Chase & Co. acquired a new stake in Evommune during the fourth quarter valued at approximately $22,408,000.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

Featured Articles

• Five stocks we like better than Evommune
• AI Server Earnings: Wall Street Sees One Clear Standout
• Navitas: NVIDIA’s AI Power Broker?
• A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
• NVIDIA’s New Power Play: Why Fluence Is Surging

Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.